Journal of Translational Medicine-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2236710, encodeId=f7bf2236e10c5, content=偏重的研究方向：心血管;生信 经验分享：New Submission 三天，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ab49420571, createdName=ms4000001903406605, createdTime=Wed Nov 13 15:29:35 CST 2024, time=2024-11-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2237783, encodeId=18e7223e78395, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：血液 经验分享：有人遇到这种情况吗？review completed然后又变成Editor Assigned吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=13045570079, createdName=Ww__, createdTime=Tue Nov 19 14:00:06 CST 2024, time=2024-11-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237054, encodeId=8a17223e05427, content=救命小修返回已经快一个月了，还是reviewers assigned , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55475510121, createdName=beryllee, createdTime=Fri Nov 15 09:40:12 CST 2024, time=2024-11-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237278, encodeId=1cf7223e27859, content=该期刊适合转化医学领域，通常在2-3个月左右完成从投稿到接收的过程。不过，也有部分网友分享周期相对较慢一些，审稿周期可能长达5个月。 该期刊对投稿格式要求较低，适合经验丰富的作者快速投稿。（投稿时可下载近期发表的文章作为模板，按照格式要求进行修改，特别是结论到参考文献之间的内容） , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 19:13:15 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2236112, encodeId=11952236112dd, content=稿号14000+，投稿量好大啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Sat Nov 09 22:13:15 CST 2024, time=2024-11-09, status=1, ipAttribution=法国), GetPortalCommentsPageByObjectIdResponse(id=2161176, encodeId=2c5c21611e67e, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生物信息 经验分享：Accept了以后一直没有校稿和见刊，已经快两个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9588107466, createdName=ms5000000594480203, createdTime=Fri Oct 06 12:07:38 CST 2023, time=2023-10-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2231278, encodeId=c34422312e869, content=偏重的研究方向：肿瘤 经验分享：09/26 submission 10/15 under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c67b9417863, createdName=ms7000001135825628, createdTime=Thu Oct 17 07:51:42 CST 2024, time=2024-10-17, status=1, ipAttribution=日本), GetPortalCommentsPageByObjectIdResponse(id=2234003, encodeId=6472223400337, content=偏重的研究方向：临床样本加湿实验;肿瘤 经验分享：记录一下，欢迎大家交流 2024.10.15 new submission 2024.10.29 editor assigned, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e87f8826821, createdName=ms8000001015853115, createdTime=Tue Oct 29 22:13:03 CST 2024, time=2024-10-29, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2234525, encodeId=cedb223452583, content=偏重的研究方向：内科 经验分享：有人遇到过二审返稿了under review之后状态又变成review assigned吗？为什么又要邀请新审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55475510121, createdName=beryllee, createdTime=Fri Nov 01 10:36:26 CST 2024, time=2024-11-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230093, encodeId=86b42230093c0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;实验验证;生信分析 经验分享：已经10天了还是new submission，我真服了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b789465039, createdName=ms2000000351369451, createdTime=Thu Oct 10 09:17:34 CST 2024, time=2024-10-10, status=1, ipAttribution=天津)]

2024-11-13 ms4000001903406605 来自山东省

偏重的研究方向：心血管;生信
经验分享：New Submission 三天，等待中

23 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2236710, encodeId=f7bf2236e10c5, content=偏重的研究方向：心血管;生信 经验分享：New Submission 三天，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ab49420571, createdName=ms4000001903406605, createdTime=Wed Nov 13 15:29:35 CST 2024, time=2024-11-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2237783, encodeId=18e7223e78395, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：血液 经验分享：有人遇到这种情况吗？review completed然后又变成Editor Assigned吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=13045570079, createdName=Ww__, createdTime=Tue Nov 19 14:00:06 CST 2024, time=2024-11-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237054, encodeId=8a17223e05427, content=救命小修返回已经快一个月了，还是reviewers assigned , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55475510121, createdName=beryllee, createdTime=Fri Nov 15 09:40:12 CST 2024, time=2024-11-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237278, encodeId=1cf7223e27859, content=该期刊适合转化医学领域，通常在2-3个月左右完成从投稿到接收的过程。不过，也有部分网友分享周期相对较慢一些，审稿周期可能长达5个月。 该期刊对投稿格式要求较低，适合经验丰富的作者快速投稿。（投稿时可下载近期发表的文章作为模板，按照格式要求进行修改，特别是结论到参考文献之间的内容） , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 19:13:15 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2236112, encodeId=11952236112dd, content=稿号14000+，投稿量好大啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Sat Nov 09 22:13:15 CST 2024, time=2024-11-09, status=1, ipAttribution=法国), GetPortalCommentsPageByObjectIdResponse(id=2161176, encodeId=2c5c21611e67e, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生物信息 经验分享：Accept了以后一直没有校稿和见刊，已经快两个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9588107466, createdName=ms5000000594480203, createdTime=Fri Oct 06 12:07:38 CST 2023, time=2023-10-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2231278, encodeId=c34422312e869, content=偏重的研究方向：肿瘤 经验分享：09/26 submission 10/15 under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c67b9417863, createdName=ms7000001135825628, createdTime=Thu Oct 17 07:51:42 CST 2024, time=2024-10-17, status=1, ipAttribution=日本), GetPortalCommentsPageByObjectIdResponse(id=2234003, encodeId=6472223400337, content=偏重的研究方向：临床样本加湿实验;肿瘤 经验分享：记录一下，欢迎大家交流 2024.10.15 new submission 2024.10.29 editor assigned, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e87f8826821, createdName=ms8000001015853115, createdTime=Tue Oct 29 22:13:03 CST 2024, time=2024-10-29, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2234525, encodeId=cedb223452583, content=偏重的研究方向：内科 经验分享：有人遇到过二审返稿了under review之后状态又变成review assigned吗？为什么又要邀请新审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55475510121, createdName=beryllee, createdTime=Fri Nov 01 10:36:26 CST 2024, time=2024-11-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230093, encodeId=86b42230093c0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;实验验证;生信分析 经验分享：已经10天了还是new submission，我真服了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b789465039, createdName=ms2000000351369451, createdTime=Thu Oct 10 09:17:34 CST 2024, time=2024-10-10, status=1, ipAttribution=天津)]

2024-11-19 Ww__ 来自浙江省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：血液
经验分享：有人遇到这种情况吗？review completed然后又变成Editor Assigned吗？

18 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2236710, encodeId=f7bf2236e10c5, content=偏重的研究方向：心血管;生信 经验分享：New Submission 三天，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ab49420571, createdName=ms4000001903406605, createdTime=Wed Nov 13 15:29:35 CST 2024, time=2024-11-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2237783, encodeId=18e7223e78395, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：血液 经验分享：有人遇到这种情况吗？review completed然后又变成Editor Assigned吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=13045570079, createdName=Ww__, createdTime=Tue Nov 19 14:00:06 CST 2024, time=2024-11-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237054, encodeId=8a17223e05427, content=救命小修返回已经快一个月了，还是reviewers assigned , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55475510121, createdName=beryllee, createdTime=Fri Nov 15 09:40:12 CST 2024, time=2024-11-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237278, encodeId=1cf7223e27859, content=该期刊适合转化医学领域，通常在2-3个月左右完成从投稿到接收的过程。不过，也有部分网友分享周期相对较慢一些，审稿周期可能长达5个月。 该期刊对投稿格式要求较低，适合经验丰富的作者快速投稿。（投稿时可下载近期发表的文章作为模板，按照格式要求进行修改，特别是结论到参考文献之间的内容） , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 19:13:15 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2236112, encodeId=11952236112dd, content=稿号14000+，投稿量好大啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Sat Nov 09 22:13:15 CST 2024, time=2024-11-09, status=1, ipAttribution=法国), GetPortalCommentsPageByObjectIdResponse(id=2161176, encodeId=2c5c21611e67e, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生物信息 经验分享：Accept了以后一直没有校稿和见刊，已经快两个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9588107466, createdName=ms5000000594480203, createdTime=Fri Oct 06 12:07:38 CST 2023, time=2023-10-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2231278, encodeId=c34422312e869, content=偏重的研究方向：肿瘤 经验分享：09/26 submission 10/15 under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c67b9417863, createdName=ms7000001135825628, createdTime=Thu Oct 17 07:51:42 CST 2024, time=2024-10-17, status=1, ipAttribution=日本), GetPortalCommentsPageByObjectIdResponse(id=2234003, encodeId=6472223400337, content=偏重的研究方向：临床样本加湿实验;肿瘤 经验分享：记录一下，欢迎大家交流 2024.10.15 new submission 2024.10.29 editor assigned, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e87f8826821, createdName=ms8000001015853115, createdTime=Tue Oct 29 22:13:03 CST 2024, time=2024-10-29, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2234525, encodeId=cedb223452583, content=偏重的研究方向：内科 经验分享：有人遇到过二审返稿了under review之后状态又变成review assigned吗？为什么又要邀请新审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55475510121, createdName=beryllee, createdTime=Fri Nov 01 10:36:26 CST 2024, time=2024-11-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230093, encodeId=86b42230093c0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;实验验证;生信分析 经验分享：已经10天了还是new submission，我真服了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b789465039, createdName=ms2000000351369451, createdTime=Thu Oct 10 09:17:34 CST 2024, time=2024-10-10, status=1, ipAttribution=天津)]

2024-11-15 beryllee 来自浙江省

救命小修返回已经快一个月了，还是reviewers assigned

18 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2236710, encodeId=f7bf2236e10c5, content=偏重的研究方向：心血管;生信 经验分享：New Submission 三天，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ab49420571, createdName=ms4000001903406605, createdTime=Wed Nov 13 15:29:35 CST 2024, time=2024-11-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2237783, encodeId=18e7223e78395, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：血液 经验分享：有人遇到这种情况吗？review completed然后又变成Editor Assigned吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=13045570079, createdName=Ww__, createdTime=Tue Nov 19 14:00:06 CST 2024, time=2024-11-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237054, encodeId=8a17223e05427, content=救命小修返回已经快一个月了，还是reviewers assigned , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55475510121, createdName=beryllee, createdTime=Fri Nov 15 09:40:12 CST 2024, time=2024-11-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237278, encodeId=1cf7223e27859, content=该期刊适合转化医学领域，通常在2-3个月左右完成从投稿到接收的过程。不过，也有部分网友分享周期相对较慢一些，审稿周期可能长达5个月。 该期刊对投稿格式要求较低，适合经验丰富的作者快速投稿。（投稿时可下载近期发表的文章作为模板，按照格式要求进行修改，特别是结论到参考文献之间的内容） , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 19:13:15 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2236112, encodeId=11952236112dd, content=稿号14000+，投稿量好大啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Sat Nov 09 22:13:15 CST 2024, time=2024-11-09, status=1, ipAttribution=法国), GetPortalCommentsPageByObjectIdResponse(id=2161176, encodeId=2c5c21611e67e, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生物信息 经验分享：Accept了以后一直没有校稿和见刊，已经快两个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9588107466, createdName=ms5000000594480203, createdTime=Fri Oct 06 12:07:38 CST 2023, time=2023-10-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2231278, encodeId=c34422312e869, content=偏重的研究方向：肿瘤 经验分享：09/26 submission 10/15 under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c67b9417863, createdName=ms7000001135825628, createdTime=Thu Oct 17 07:51:42 CST 2024, time=2024-10-17, status=1, ipAttribution=日本), GetPortalCommentsPageByObjectIdResponse(id=2234003, encodeId=6472223400337, content=偏重的研究方向：临床样本加湿实验;肿瘤 经验分享：记录一下，欢迎大家交流 2024.10.15 new submission 2024.10.29 editor assigned, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e87f8826821, createdName=ms8000001015853115, createdTime=Tue Oct 29 22:13:03 CST 2024, time=2024-10-29, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2234525, encodeId=cedb223452583, content=偏重的研究方向：内科 经验分享：有人遇到过二审返稿了under review之后状态又变成review assigned吗？为什么又要邀请新审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55475510121, createdName=beryllee, createdTime=Fri Nov 01 10:36:26 CST 2024, time=2024-11-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230093, encodeId=86b42230093c0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;实验验证;生信分析 经验分享：已经10天了还是new submission，我真服了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b789465039, createdName=ms2000000351369451, createdTime=Thu Oct 10 09:17:34 CST 2024, time=2024-10-10, status=1, ipAttribution=天津)]

2024-11-16 ms1000001788822136 来自上海

该期刊适合转化医学领域，通常在2-3个月左右完成从投稿到接收的过程。不过，也有部分网友分享周期相对较慢一些，审稿周期可能长达5个月。
该期刊对投稿格式要求较低，适合经验丰富的作者快速投稿。（投稿时可下载近期发表的文章作为模板，按照格式要求进行修改，特别是结论到参考文献之间的内容）

20 0

[GetPortalCommentsPageByObjectIdResponse(id=2236710, encodeId=f7bf2236e10c5, content=偏重的研究方向：心血管;生信 经验分享：New Submission 三天，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ab49420571, createdName=ms4000001903406605, createdTime=Wed Nov 13 15:29:35 CST 2024, time=2024-11-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2237783, encodeId=18e7223e78395, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：血液 经验分享：有人遇到这种情况吗？review completed然后又变成Editor Assigned吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=13045570079, createdName=Ww__, createdTime=Tue Nov 19 14:00:06 CST 2024, time=2024-11-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237054, encodeId=8a17223e05427, content=救命小修返回已经快一个月了，还是reviewers assigned , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55475510121, createdName=beryllee, createdTime=Fri Nov 15 09:40:12 CST 2024, time=2024-11-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237278, encodeId=1cf7223e27859, content=该期刊适合转化医学领域，通常在2-3个月左右完成从投稿到接收的过程。不过，也有部分网友分享周期相对较慢一些，审稿周期可能长达5个月。 该期刊对投稿格式要求较低，适合经验丰富的作者快速投稿。（投稿时可下载近期发表的文章作为模板，按照格式要求进行修改，特别是结论到参考文献之间的内容） , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 19:13:15 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2236112, encodeId=11952236112dd, content=稿号14000+，投稿量好大啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Sat Nov 09 22:13:15 CST 2024, time=2024-11-09, status=1, ipAttribution=法国), GetPortalCommentsPageByObjectIdResponse(id=2161176, encodeId=2c5c21611e67e, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生物信息 经验分享：Accept了以后一直没有校稿和见刊，已经快两个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9588107466, createdName=ms5000000594480203, createdTime=Fri Oct 06 12:07:38 CST 2023, time=2023-10-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2231278, encodeId=c34422312e869, content=偏重的研究方向：肿瘤 经验分享：09/26 submission 10/15 under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c67b9417863, createdName=ms7000001135825628, createdTime=Thu Oct 17 07:51:42 CST 2024, time=2024-10-17, status=1, ipAttribution=日本), GetPortalCommentsPageByObjectIdResponse(id=2234003, encodeId=6472223400337, content=偏重的研究方向：临床样本加湿实验;肿瘤 经验分享：记录一下，欢迎大家交流 2024.10.15 new submission 2024.10.29 editor assigned, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e87f8826821, createdName=ms8000001015853115, createdTime=Tue Oct 29 22:13:03 CST 2024, time=2024-10-29, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2234525, encodeId=cedb223452583, content=偏重的研究方向：内科 经验分享：有人遇到过二审返稿了under review之后状态又变成review assigned吗？为什么又要邀请新审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55475510121, createdName=beryllee, createdTime=Fri Nov 01 10:36:26 CST 2024, time=2024-11-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230093, encodeId=86b42230093c0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;实验验证;生信分析 经验分享：已经10天了还是new submission，我真服了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b789465039, createdName=ms2000000351369451, createdTime=Thu Oct 10 09:17:34 CST 2024, time=2024-10-10, status=1, ipAttribution=天津)]

2024-11-09 ms3000000851999119 来自法国

稿号14000+，投稿量好大啊

23 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2236710, encodeId=f7bf2236e10c5, content=偏重的研究方向：心血管;生信 经验分享：New Submission 三天，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ab49420571, createdName=ms4000001903406605, createdTime=Wed Nov 13 15:29:35 CST 2024, time=2024-11-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2237783, encodeId=18e7223e78395, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：血液 经验分享：有人遇到这种情况吗？review completed然后又变成Editor Assigned吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=13045570079, createdName=Ww__, createdTime=Tue Nov 19 14:00:06 CST 2024, time=2024-11-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237054, encodeId=8a17223e05427, content=救命小修返回已经快一个月了，还是reviewers assigned , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55475510121, createdName=beryllee, createdTime=Fri Nov 15 09:40:12 CST 2024, time=2024-11-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237278, encodeId=1cf7223e27859, content=该期刊适合转化医学领域，通常在2-3个月左右完成从投稿到接收的过程。不过，也有部分网友分享周期相对较慢一些，审稿周期可能长达5个月。 该期刊对投稿格式要求较低，适合经验丰富的作者快速投稿。（投稿时可下载近期发表的文章作为模板，按照格式要求进行修改，特别是结论到参考文献之间的内容） , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 19:13:15 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2236112, encodeId=11952236112dd, content=稿号14000+，投稿量好大啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Sat Nov 09 22:13:15 CST 2024, time=2024-11-09, status=1, ipAttribution=法国), GetPortalCommentsPageByObjectIdResponse(id=2161176, encodeId=2c5c21611e67e, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生物信息 经验分享：Accept了以后一直没有校稿和见刊，已经快两个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9588107466, createdName=ms5000000594480203, createdTime=Fri Oct 06 12:07:38 CST 2023, time=2023-10-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2231278, encodeId=c34422312e869, content=偏重的研究方向：肿瘤 经验分享：09/26 submission 10/15 under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c67b9417863, createdName=ms7000001135825628, createdTime=Thu Oct 17 07:51:42 CST 2024, time=2024-10-17, status=1, ipAttribution=日本), GetPortalCommentsPageByObjectIdResponse(id=2234003, encodeId=6472223400337, content=偏重的研究方向：临床样本加湿实验;肿瘤 经验分享：记录一下，欢迎大家交流 2024.10.15 new submission 2024.10.29 editor assigned, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e87f8826821, createdName=ms8000001015853115, createdTime=Tue Oct 29 22:13:03 CST 2024, time=2024-10-29, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2234525, encodeId=cedb223452583, content=偏重的研究方向：内科 经验分享：有人遇到过二审返稿了under review之后状态又变成review assigned吗？为什么又要邀请新审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55475510121, createdName=beryllee, createdTime=Fri Nov 01 10:36:26 CST 2024, time=2024-11-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230093, encodeId=86b42230093c0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;实验验证;生信分析 经验分享：已经10天了还是new submission，我真服了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b789465039, createdName=ms2000000351369451, createdTime=Thu Oct 10 09:17:34 CST 2024, time=2024-10-10, status=1, ipAttribution=天津)]

2023-10-06 ms5000000594480203 来自北京

审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤;生物信息
经验分享：Accept了以后一直没有校稿和见刊，已经快两个月了，这正常吗？

145 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2236710, encodeId=f7bf2236e10c5, content=偏重的研究方向：心血管;生信 经验分享：New Submission 三天，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ab49420571, createdName=ms4000001903406605, createdTime=Wed Nov 13 15:29:35 CST 2024, time=2024-11-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2237783, encodeId=18e7223e78395, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：血液 经验分享：有人遇到这种情况吗？review completed然后又变成Editor Assigned吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=13045570079, createdName=Ww__, createdTime=Tue Nov 19 14:00:06 CST 2024, time=2024-11-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237054, encodeId=8a17223e05427, content=救命小修返回已经快一个月了，还是reviewers assigned , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55475510121, createdName=beryllee, createdTime=Fri Nov 15 09:40:12 CST 2024, time=2024-11-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237278, encodeId=1cf7223e27859, content=该期刊适合转化医学领域，通常在2-3个月左右完成从投稿到接收的过程。不过，也有部分网友分享周期相对较慢一些，审稿周期可能长达5个月。 该期刊对投稿格式要求较低，适合经验丰富的作者快速投稿。（投稿时可下载近期发表的文章作为模板，按照格式要求进行修改，特别是结论到参考文献之间的内容） , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 19:13:15 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2236112, encodeId=11952236112dd, content=稿号14000+，投稿量好大啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Sat Nov 09 22:13:15 CST 2024, time=2024-11-09, status=1, ipAttribution=法国), GetPortalCommentsPageByObjectIdResponse(id=2161176, encodeId=2c5c21611e67e, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生物信息 经验分享：Accept了以后一直没有校稿和见刊，已经快两个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9588107466, createdName=ms5000000594480203, createdTime=Fri Oct 06 12:07:38 CST 2023, time=2023-10-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2231278, encodeId=c34422312e869, content=偏重的研究方向：肿瘤 经验分享：09/26 submission 10/15 under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c67b9417863, createdName=ms7000001135825628, createdTime=Thu Oct 17 07:51:42 CST 2024, time=2024-10-17, status=1, ipAttribution=日本), GetPortalCommentsPageByObjectIdResponse(id=2234003, encodeId=6472223400337, content=偏重的研究方向：临床样本加湿实验;肿瘤 经验分享：记录一下，欢迎大家交流 2024.10.15 new submission 2024.10.29 editor assigned, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e87f8826821, createdName=ms8000001015853115, createdTime=Tue Oct 29 22:13:03 CST 2024, time=2024-10-29, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2234525, encodeId=cedb223452583, content=偏重的研究方向：内科 经验分享：有人遇到过二审返稿了under review之后状态又变成review assigned吗？为什么又要邀请新审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55475510121, createdName=beryllee, createdTime=Fri Nov 01 10:36:26 CST 2024, time=2024-11-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230093, encodeId=86b42230093c0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;实验验证;生信分析 经验分享：已经10天了还是new submission，我真服了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b789465039, createdName=ms2000000351369451, createdTime=Thu Oct 10 09:17:34 CST 2024, time=2024-10-10, status=1, ipAttribution=天津)]

2024-10-17 ms7000001135825628 来自日本

偏重的研究方向：肿瘤
经验分享：09/26 submission 10/15 under review

29 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2236710, encodeId=f7bf2236e10c5, content=偏重的研究方向：心血管;生信 经验分享：New Submission 三天，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ab49420571, createdName=ms4000001903406605, createdTime=Wed Nov 13 15:29:35 CST 2024, time=2024-11-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2237783, encodeId=18e7223e78395, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：血液 经验分享：有人遇到这种情况吗？review completed然后又变成Editor Assigned吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=13045570079, createdName=Ww__, createdTime=Tue Nov 19 14:00:06 CST 2024, time=2024-11-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237054, encodeId=8a17223e05427, content=救命小修返回已经快一个月了，还是reviewers assigned , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55475510121, createdName=beryllee, createdTime=Fri Nov 15 09:40:12 CST 2024, time=2024-11-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237278, encodeId=1cf7223e27859, content=该期刊适合转化医学领域，通常在2-3个月左右完成从投稿到接收的过程。不过，也有部分网友分享周期相对较慢一些，审稿周期可能长达5个月。 该期刊对投稿格式要求较低，适合经验丰富的作者快速投稿。（投稿时可下载近期发表的文章作为模板，按照格式要求进行修改，特别是结论到参考文献之间的内容） , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 19:13:15 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2236112, encodeId=11952236112dd, content=稿号14000+，投稿量好大啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Sat Nov 09 22:13:15 CST 2024, time=2024-11-09, status=1, ipAttribution=法国), GetPortalCommentsPageByObjectIdResponse(id=2161176, encodeId=2c5c21611e67e, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生物信息 经验分享：Accept了以后一直没有校稿和见刊，已经快两个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9588107466, createdName=ms5000000594480203, createdTime=Fri Oct 06 12:07:38 CST 2023, time=2023-10-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2231278, encodeId=c34422312e869, content=偏重的研究方向：肿瘤 经验分享：09/26 submission 10/15 under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c67b9417863, createdName=ms7000001135825628, createdTime=Thu Oct 17 07:51:42 CST 2024, time=2024-10-17, status=1, ipAttribution=日本), GetPortalCommentsPageByObjectIdResponse(id=2234003, encodeId=6472223400337, content=偏重的研究方向：临床样本加湿实验;肿瘤 经验分享：记录一下，欢迎大家交流 2024.10.15 new submission 2024.10.29 editor assigned, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e87f8826821, createdName=ms8000001015853115, createdTime=Tue Oct 29 22:13:03 CST 2024, time=2024-10-29, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2234525, encodeId=cedb223452583, content=偏重的研究方向：内科 经验分享：有人遇到过二审返稿了under review之后状态又变成review assigned吗？为什么又要邀请新审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55475510121, createdName=beryllee, createdTime=Fri Nov 01 10:36:26 CST 2024, time=2024-11-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230093, encodeId=86b42230093c0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;实验验证;生信分析 经验分享：已经10天了还是new submission，我真服了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b789465039, createdName=ms2000000351369451, createdTime=Thu Oct 10 09:17:34 CST 2024, time=2024-10-10, status=1, ipAttribution=天津)]

2024-10-29 ms8000001015853115 来自上海

偏重的研究方向：临床样本加湿实验;肿瘤
经验分享：记录一下，欢迎大家交流
2024.10.15 new submission
2024.10.29 editor assigned

2 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2236710, encodeId=f7bf2236e10c5, content=偏重的研究方向：心血管;生信 经验分享：New Submission 三天，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ab49420571, createdName=ms4000001903406605, createdTime=Wed Nov 13 15:29:35 CST 2024, time=2024-11-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2237783, encodeId=18e7223e78395, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：血液 经验分享：有人遇到这种情况吗？review completed然后又变成Editor Assigned吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=13045570079, createdName=Ww__, createdTime=Tue Nov 19 14:00:06 CST 2024, time=2024-11-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237054, encodeId=8a17223e05427, content=救命小修返回已经快一个月了，还是reviewers assigned , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55475510121, createdName=beryllee, createdTime=Fri Nov 15 09:40:12 CST 2024, time=2024-11-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237278, encodeId=1cf7223e27859, content=该期刊适合转化医学领域，通常在2-3个月左右完成从投稿到接收的过程。不过，也有部分网友分享周期相对较慢一些，审稿周期可能长达5个月。 该期刊对投稿格式要求较低，适合经验丰富的作者快速投稿。（投稿时可下载近期发表的文章作为模板，按照格式要求进行修改，特别是结论到参考文献之间的内容） , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 19:13:15 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2236112, encodeId=11952236112dd, content=稿号14000+，投稿量好大啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Sat Nov 09 22:13:15 CST 2024, time=2024-11-09, status=1, ipAttribution=法国), GetPortalCommentsPageByObjectIdResponse(id=2161176, encodeId=2c5c21611e67e, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生物信息 经验分享：Accept了以后一直没有校稿和见刊，已经快两个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9588107466, createdName=ms5000000594480203, createdTime=Fri Oct 06 12:07:38 CST 2023, time=2023-10-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2231278, encodeId=c34422312e869, content=偏重的研究方向：肿瘤 经验分享：09/26 submission 10/15 under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c67b9417863, createdName=ms7000001135825628, createdTime=Thu Oct 17 07:51:42 CST 2024, time=2024-10-17, status=1, ipAttribution=日本), GetPortalCommentsPageByObjectIdResponse(id=2234003, encodeId=6472223400337, content=偏重的研究方向：临床样本加湿实验;肿瘤 经验分享：记录一下，欢迎大家交流 2024.10.15 new submission 2024.10.29 editor assigned, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e87f8826821, createdName=ms8000001015853115, createdTime=Tue Oct 29 22:13:03 CST 2024, time=2024-10-29, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2234525, encodeId=cedb223452583, content=偏重的研究方向：内科 经验分享：有人遇到过二审返稿了under review之后状态又变成review assigned吗？为什么又要邀请新审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55475510121, createdName=beryllee, createdTime=Fri Nov 01 10:36:26 CST 2024, time=2024-11-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230093, encodeId=86b42230093c0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;实验验证;生信分析 经验分享：已经10天了还是new submission，我真服了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b789465039, createdName=ms2000000351369451, createdTime=Thu Oct 10 09:17:34 CST 2024, time=2024-10-10, status=1, ipAttribution=天津)]

2024-11-01 beryllee 来自北京

偏重的研究方向：内科
经验分享：有人遇到过二审返稿了under review之后状态又变成review assigned吗？为什么又要邀请新审稿人

20 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2236710, encodeId=f7bf2236e10c5, content=偏重的研究方向：心血管;生信 经验分享：New Submission 三天，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ab49420571, createdName=ms4000001903406605, createdTime=Wed Nov 13 15:29:35 CST 2024, time=2024-11-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2237783, encodeId=18e7223e78395, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：血液 经验分享：有人遇到这种情况吗？review completed然后又变成Editor Assigned吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=13045570079, createdName=Ww__, createdTime=Tue Nov 19 14:00:06 CST 2024, time=2024-11-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237054, encodeId=8a17223e05427, content=救命小修返回已经快一个月了，还是reviewers assigned , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55475510121, createdName=beryllee, createdTime=Fri Nov 15 09:40:12 CST 2024, time=2024-11-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237278, encodeId=1cf7223e27859, content=该期刊适合转化医学领域，通常在2-3个月左右完成从投稿到接收的过程。不过，也有部分网友分享周期相对较慢一些，审稿周期可能长达5个月。 该期刊对投稿格式要求较低，适合经验丰富的作者快速投稿。（投稿时可下载近期发表的文章作为模板，按照格式要求进行修改，特别是结论到参考文献之间的内容） , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 19:13:15 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2236112, encodeId=11952236112dd, content=稿号14000+，投稿量好大啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Sat Nov 09 22:13:15 CST 2024, time=2024-11-09, status=1, ipAttribution=法国), GetPortalCommentsPageByObjectIdResponse(id=2161176, encodeId=2c5c21611e67e, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;生物信息 经验分享：Accept了以后一直没有校稿和见刊，已经快两个月了，这正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9588107466, createdName=ms5000000594480203, createdTime=Fri Oct 06 12:07:38 CST 2023, time=2023-10-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2231278, encodeId=c34422312e869, content=偏重的研究方向：肿瘤 经验分享：09/26 submission 10/15 under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c67b9417863, createdName=ms7000001135825628, createdTime=Thu Oct 17 07:51:42 CST 2024, time=2024-10-17, status=1, ipAttribution=日本), GetPortalCommentsPageByObjectIdResponse(id=2234003, encodeId=6472223400337, content=偏重的研究方向：临床样本加湿实验;肿瘤 经验分享：记录一下，欢迎大家交流 2024.10.15 new submission 2024.10.29 editor assigned, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e87f8826821, createdName=ms8000001015853115, createdTime=Tue Oct 29 22:13:03 CST 2024, time=2024-10-29, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2234525, encodeId=cedb223452583, content=偏重的研究方向：内科 经验分享：有人遇到过二审返稿了under review之后状态又变成review assigned吗？为什么又要邀请新审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55475510121, createdName=beryllee, createdTime=Fri Nov 01 10:36:26 CST 2024, time=2024-11-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230093, encodeId=86b42230093c0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;实验验证;生信分析 经验分享：已经10天了还是new submission，我真服了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b789465039, createdName=ms2000000351369451, createdTime=Thu Oct 10 09:17:34 CST 2024, time=2024-10-10, status=1, ipAttribution=天津)]

2024-10-10 ms2000000351369451 来自天津

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤;实验验证;生信分析
经验分享：已经10天了还是new submission，我真服了

44 7

展开7条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务